SNDX
Research Snapshot
Static fundamentals, valuation context, and investor signals for Syndax Pharmaceuticals, Inc. (SNDX).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-441.6%
ROIC, -187.5% FCF margin
Growth
157.7%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 4.4x current ratio
Superinvestors
1
Top: Torray Funds (0.4%)
Strengths to research
- Revenue compounded at 157.7% over five years.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Free cash flow margin is negative at -187.5%.
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for SNDX.
Grade F
21
/ 100
Financial Charts
No financial data available for SNDX (annual).
1 superinvestors own SNDX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Torray Funds Torray Funds | 104,868 | $2M | 0.38% | 0.0% |